Heart failure epidemiology and novel treatments in Japan: facts and numbers

ESC heart failure - Tập 3 Số 3 - Trang 145-151 - 2016
Masaaki Konishi1, Junichi Ishida1, Jochen Springer1, Stephan von Haehling1, Yoshihiro J. Akashi2, Hiroaki Shimokawa3, Stefan D. Anker1
1Innovative Clinical Trials, Department of Cardiology and Pneumology, University of Göttingen Medical School, Göttingen, Germany
2Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
3Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Tóm tắt

AbstractJapan has the highest proportion of older people in the world, 25.9% of the population were aged 65 or above in 2014. Although there have been no population‐based studies that precisely examined the prevalence of heart failure in Japan, one report estimated the number of Japanese outpatients with left ventricular dysfunction was 979, 000 (0.8% of total population), which was projected to increase gradually as the population ages, reaching 1.3 million by 2030. Ischemic etiology was less frequently observed in Japan (31–47%) than in western population (54–57%). The prevalence of HF with preserved ejection fraction was similar between Japan (34–68%) and western countries (34–51%). Non‐cardiac co‐morbidities such as chronic obstructive pulmonary diseases and anemia were observed in 6–9% in Japan and 19–31% in western countries, and 35–58% in Japan and 37–56% in western countries, respectively. The definition of chronic kidney disease widely differed among studies. A relatively good survival prognosis in Japanese patients has been discussed. One‐year mortality after discharge from initial hospitalization was 9–12%, which seems to be better than the western cohort. Although length of stay was remarkably longer in Japan (15–21 days) than western countries (4–9 days), it will have to be shortened, as Japan is now being faced with an upcoming HF pandemic. Some treatments in Japan are not approved outside Japan. Such treatments include carperitide infusion (used in 58% of hospitalized HF), nicorandil infusion (9.6%), and oral pimobendan (5%). More recently, landiolol and tolvaptan have been approved. Although these drugs might have a potential to be an effective therapeutic option, lack of corroborating evidence in many of such treatments would emphasize the need for larger clinical trials.

Từ khóa


Tài liệu tham khảo

Homepage of Statistics Bureau.Ministry of Internal Affairs and Communications Japan.http://www.stat.go.jp/english/data/jinsui/tsuki/index.htm. (5 October 2015).

10.2165/00019053-199609030-00002

10.1016/0735-1097(93)90455-A

10.1253/circj.72.489

10.1002/ejhf.319

10.1002/ehf2.12005

10.1253/circj.CJ-13-0187

10.1253/circj.CJ-11-1196

10.1253/circj.CJ-11-0135

10.1093/eurheartj/ehl193

10.1016/j.ahj.2004.08.005

10.1253/circj.70.1617

10.1253/circj.CJ-09-0254

10.1016/j.ijcard.2015.04.258

10.1093/eurjhf/hfq002

10.1093/eurheartj/ehl407

10.1001/archinte.168.8.847

10.1253/circj.CJ-14-0939

10.1253/circj.CJ-15-0514

10.1253/circj.CJ-13-0971

10.1016/j.jjcc.2013.03.009

10.1253/circj.CJ-08-0323

10.1016/j.jacc.2007.04.064

10.1016/j.jacc.2005.09.022

10.1016/j.ahj.2007.03.012

10.1016/j.ahj.2008.04.030

10.1177/2048872615593387

10.1253/circj.CJ-15-0174

10.1253/circj.CJ-09-0184

10.1016/j.cardfail.2005.09.005

10.1093/eurheartj/ehn539

10.1253/circj.CJ-15-0975

10.1016/j.pcad.2013.12.001

10.1038/324473a0

10.1253/circj.CJ-66-0068

10.1253/circj.CJ-08-0130

10.1016/j.jacc.2011.03.056

10.1016/j.jacc.2008.10.061

Matsue Y, 2015, Carperitide Is associated with increased in‐hospital mortality in acute heart failure: a propensity score‐matched analysis, J Card Fail, 18

10.1111/1755-5922.12097

10.1253/circj.CJ-12-1618

10.1016/S0735-1097(98)00297-6

10.1001/jama.297.12.1332

10.1001/jama.297.12.1319

Matsue Y, 2014, Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study, Int Soc Cardiovasc Pharmacother, 28, 73

10.1111/1755-5922.12142

10.1253/circj.CJ-13-1255

10.1536/ihj.14-248

10.1136/hrt.76.3.223

10.1253/circj.66.149

Taylor J, 2011, Recent pioneering cardiology developments in Japan: Japanese cardiologists have discovered Waon therapy for severe or refractory heart failure and extracorporeal cardiac shock wave therapy for severe angina pectoris, Eur Heart J, 32, 1690

10.1016/j.jjcc.2008.07.009

Thông tin
Thông tin xuất bản

ESC heart failure

Tập 3 Số 3

145-151

Thông tin tác giả